Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Gyre Therapeutics Inc (GYRE)

NASDAQ
Currency in USD
Disclaimer
17.1100
+0.7800(+4.78%)
Closed

GYRE Comments

needs better leadership
RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
hope that in long term it will rise
Phase 1/2 completion of dosing announced June 14, 2017 with data due by the end of September.. Data will be excellent! The stock will rock once again!
To holders of CBIO: Patience will pay off. Between now and December we should have a major event that would restore the fair price to this stock.
Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program. . 8:01 am ET September 11, 2017 (Globe Newswire) Print
CBIO is warming up to something. Maybe good news is in the way. I feel something good is coming
why are you selling your shares cheep. Some one is accumulating for the big day.
Watch out for $CBIO as secondary offering lock-up expires tomorrow 7/6/17
Something I read from an analyst opinion column today about this . . This is a great news for $CBIO for being able to partner with "ISU Abxis"ISU Abxis is the beggest Biotech ion Korea with annual revenue of $30B.. Furthermore, they are doing some fantastic blood cancer work. If they agreed to $CBIO data, that means something....
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.